To explore whether the therapeutic effects of FGF21 on vascular function applied to T1D, we established an STZ-induced T1D mouse model and treated these mice with 30 days of rFGF21 injection (i.p., 0.5 mg/Kg body weight). This evidence concerns the gene FGF21 and type 1 diabetes mellitus.